Nothing leaves unproven.

Most pharmacies dispense what a manufacturer made: a fixed strength, a fixed form, produced in mass lots. That works, until it doesn’t. A patient needs a dose that was never commercialized. A widely used medication goes into shortage. A protocol calls for a strength, a combination or a delivery form the shelf simply doesn’t carry. That gap, between what is manufactured and what a patient actually needs, is where compounding lives.

It has never mattered more. Demand for GLP-1 therapies, peptides and personalized protocols has outrun the supply chain, and providers are left looking for a partner who can prepare exactly what they prescribe, reliably and legally. InterX Pharmacy is that partner. We are a 503A compounding pharmacy in Miami, Florida, and 503A compounding is a legal, regulated pathway for preparing patient-specific preparations, including peptides like Tirzepatide and Retatrutide, against a valid prescription. We operate fully within it, registered with the FDA and licensed by the State of Florida.

But access is only half the work. The other half is trust. When a compounded vial arrives at a clinic, the provider usually has no way to know whether the strength on the label is the strength inside, whether it’s pure, whether it’s sterile. They prescribe on faith. We think that’s the wrong way to run a pharmacy your patients depend on.

So every preparation we make is compounded to the exact formula, tested for identity, potency and sterility, and released with its own certificate of analysis. The COA travels with the order. A provider can see the evidence before a single dose is given, and a patient can fill a prescription knowing exactly what is in the bottle. The proof isn’t a marketing line for us. It’s the product.